Last updated 2026-07-26
- Raised $80M Series D led by Nvidia, Jul 2024
- Raised $20M convertible note led by Pfizer, Sep 2022
- Raised $8M Series B led by OurCrowd, Aug 2021
Total raised
$121.6M
Last: Undisclosed Round 2024-07
Stage
Series C
Founded
2016
Headcount
130
HQ
-, Israel
Sector
Health Tech & Life Sciences
About
CytoReason is a technology company developing a computational model of the human body that simulates human disease on a cellular level, minimizes the need for animal trials, and makes human trials more focused and accurate.
With CytoReason's proprietary database and AI-led platform, pharmaceutical and biotechnology companies can make data-driven decisions quickly and cost effectively. To date, five of the world’s top ten pharma companies use CytoReason’s technology to identify new opportunities, shorten trial phases, reduce development costs, and increase the likelihood of drug approval.
Funding history · 6 rounds · $121.6M total
2024-07
D Round
$80.0M
★ Nvidia★ Pfizer★ OurCrowd★ Bank Hapoalim★ Thermo Fisher Scientific
2024-04
C Round
Undisclosed
★ OurCrowd
2022-09
Convertible Debt
$20.0M
★ PfizerOurCrowd
2021-08
B Round
$8.0M
★ OurCrowd
2020-06
A Round
$10.8M
★ OurCrowd
2019-12
Seed
$2.8M
★ Pontifax★ PICO Venture Partners
Headcount over time
From 15 (2018-07) to 116 (2026-03) · +101 (+673%) · 22 points · source: Finder history + radar grounding
Q&A
- What is CytoReason's primary focus?
- CytoReason is a technology company that develops a computational model of the human body to simulate human disease at a cellular level, aiming to reduce the need for animal trials and enhance the focus and accuracy of human trials.
- Which major pharmaceutical companies utilize CytoReason's technology?
- Five of the world’s top ten pharmaceutical companies use CytoReason’s technology for data-driven decisions in drug development.
- Has CytoReason expanded its collaboration with Sanofi recently?
- Yes, in January 2026, CytoReason announced the expansion of its collaboration with Sanofi for the third time to advance AI-driven drug discovery.
- What new AI agent did CytoReason unveil in January 2026?
- In January 2026, CytoReason unveiled LINA, an AI agent accelerated by NVIDIA for pharma R&D, built on computational disease models.
- What is the current employee count for CytoReason?
- CytoReason currently has 51–200 employees.
- When was CytoReason founded?
- CytoReason was founded in September 2016.
Team · 6
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesDigital HealthcareMedical Decision Support
Technologies
BiologicalsCellsArtificial IntelligenceMachine Learning
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticalsHealthcareProvidersLaboratories
Business model
B2B
Highlights
Verified
Tags
clinical-trialslaboratoriesartificial-intelligencehealthcare-providerspatent-pendingdrug-discoveryclinical-dataclinicsmedical-technologiesdata-analyticsdigital-healthcarebig-datapharma-companiescancermachine-learningbiotechnologybiopharmaceuticalimmunotherapyimmunologybioinformaticsmhealthautoimmune-diseasesmolecular-biologydecision-supportnatural-language-processingcells
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | cytoreason.com |
|---|---|
| linkedin.com/company/12901361 | |
| YouTube | youtube.com/channel/UC7ys04qK-C1M83XTV3NbI6g |
Identifiers & details
| Founded | 2016-9 |
|---|---|
| Employees (exact) | 130 |
Radar intelligence
Publications (Crossref)
| Works | 6 |
|---|
GitHub
| Top repos | stress-load-testing-framework, langfuse, internal-apps-front, nf-amazon, streamlit-cyto |
|---|
Web history (Wayback)
| Domain | cytoreason.com |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 515522134 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2016-09-12 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2025 |
| Active charges / liens | 0 |
| Registry events | 3 — charge (2), people (1) |
| Registered address | דרך בגין 132 תל אביב - יפו |
Recent registry events
| Date | Event |
|---|---|
| 2025-12-31 | רישום שעבוד |
| 2026-06-17 | עדכון דירקטורים-הוספת דירקטור |
| 2025-09-01 | סילוק שעבוד |